SuviCa gets positive FDA pre-IND feedback for SVC112 in solid tumors

SuviCa, the University of Colorado Boulder and CU Anschutz said the FDA gave positive pre-IND feedback on SVC112, a first-in-class protein synthesis inhibitor for advanced and metastatic solid tumors. The agency said the nonclinical package appears sufficient for a first-in-human study, clearing a key regulatory step toward an IND filing.

Why it matters: - The FDA feedback removes a major early regulatory hurdle for SVC112. - The response supports SuviCa’s path to an IND submission and a first-in-human study in patients with advanced solid tumors. - The program is aimed at cancers with aggressive growth and resistance to standard treatment.

What happened: - SuviCa, Inc., CU Boulder and CU Anschutz announced the successful completion of a Type B pre-Investigational New Drug interaction with the FDA for SVC112. - The FDA said the nonclinical studies completed, planned and ongoing for SVC112 “appear sufficient to support the proposed first-in-human study.” - The agency also said SuviCa’s proposed first-in-human starting dose “appears reasonable.”

The details: - SVC112 is SuviCa’s first-in-class protein synthesis inhibitor. - The drug is a synthetic analog of the natural product Bouvardin. - SVC112 targets eukaryotic elongation factor 2, or eEF2. - The compound has shown anti-tumor activity in preclinical studies. - SuviCa is developing SVC112 for advanced and metastatic solid tumors. - The planned Phase 1 study is open-label and includes dose-escalation and dose-expansion parts. - The trial will test intravenous SVC112 in patients with advanced or metastatic solid tumors who have exhausted standard treatment options. - The study aims to establish the recommended Phase 2 dose. - The study will also assess safety, pharmacokinetics, preliminary anti-tumor activity and biomarker response. - The FDA said it had no objections to the proposed dosing frequency if ongoing GLP toxicology studies support the regimen. - The agency recommended refinements to dose-limiting toxicity criteria. - The FDA also encouraged future discussions once preliminary clinical response data are available. - SuviCa plans to file its IND after ongoing GLP toxicology work is complete and chemistry, manufacturing and controls activities are finalized.

Between the lines: - The FDA’s written feedback suggests the program is moving from preclinical work toward clinical testing with a clearer regulatory path. - The emphasis on toxicology, dosing and dose-limiting toxicity criteria shows the agency is still shaping the trial design before first dosing. - The collaboration with CU Boulder and CU Anschutz remains central to the program’s development and inventorship. - Antonio Jimeno, a CU Anschutz professor and SuviCa board member, said the feedback represents an important milestone and supports the development strategy. - Tin Tin Su, a CU Boulder professor, lead inventor of SVC112 and SuviCa co-founder, said the university support network made the progress possible.

What's next: - SuviCa will complete ongoing GLP toxicology studies. - SuviCa will finalize CMC activities before submitting its IND. - The company will seek to start the first-in-human clinical study after IND clearance. - SuviCa and the FDA may revisit the program once early clinical response data are available.

The bottom line: - SVC112 has cleared an important pre-IND checkpoint, putting SuviCa closer to testing the cancer drug in patients for the first time.